BSECompany Update2d ago · 12 Oct 2026, 03:24 pm

Compliance Certificate Under Regulation 74 (5) for the Period ended 30th September, 2026

Bacil Pharma Ltd · 524516

✦ AI Summary

Bacil Pharma Ltd has submitted a compliance certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the period ended 30th September, 2026, confirming the dematerialization of securities and listing on stock exchanges.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Bacil Pharma Ltd - 524516 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Attachments (1)

📄

fb2c0277-dfa7-4b27-b664-334c7e54762f.pdf

pdf

Download →
View document text
Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099 Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Tel/Fax: 22618327 Date: 12-10-2026 The Manager (Listing), BSE Limited PJ Tower, Dalal Street,Fort, Mumbai – 400 001 Sub: Submission of copy of Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended 30th September, 2026 Ref.: Scrip Code: 524516, Stock Code: BACPHAR Dear Sir, We enclose herewith copy of certificate received from Bigshare Services Pvt. Ltd., Registrar and Transfer Agent of the company under above Regulations, certifying the following:- 1. The securities comprised in the certificate(s) of Security dematerialised, have been listed on stock exchanges where the earlier issued securities are listed. 2. After due verification, immediately mutilated and cancelled the certificate(s) of security received for dematerialisation. 3. Substituted in our records the name of the Depository as the registered owner and had sent a certificate to this effect to the Depositories and to every stock exchange on a quarterly basis, where the security is listed. Kindly find the same in order and acknowledge the receipt. For Bacil Pharma Limited Chaitali Kalpataru Shah Managing Director Din: 11167778 Ref No. BSS/74(5) Date: 08/10/2026 BACIL PHARMA LTD 71 LAXMI BUILDING 4TH FLOOR SIR P M ROAD FORT MUMBAI- 400001 Dear Sir/Madam, Sub: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026. Ref: NSDL/CIR/II/5/2019 dated 25th January 2019 DSL/OPS/RTA/POLICY/2019/14 dated 25th January 2019. SEBI vide its letter ref no. MRD/DOP2/DSA2/OW/2019/2498/1 dated 24/01/2019 In reference to the above – captioned regulation we hereby confirm that the securities received from the depository Participants for dematerialization up to 30th September 2026, were confirmed (accepted/rejected) to the depositories by us and that securities comprised in the said certificates have been listed on the stock exchange where the earlier issued securities are listed. We hereby confirm that the security certificates received for dematerialization have been mutilated & cancelled after due verification by the depository Participant and the name of the depositories have been substituted in register of members as registered owner within 15 days of receipt of certificate of securities. We request you to kindly take note of the above in your records. Thanking you, Yours faithfully, For Bigshare Services Pvt. Ltd., Sandeep More Authorised Signatory